Participated · Series A · Apr 2026

Dnotitia develops an AI storage stack centered on Seahorse, a vector database, and VDPU, a dedicated vector data processing semiconductor. In March the company unveiled an AI Storage Strategy to integrate external knowledge, long-term memory, and working memory. Seahorse received Korea’s top-grade GS software certification in January and Seahorse Cloud was launched as a SaaS offering in March. Dnotitia describes VDPU as a purpose-built chip for accelerating vector data search and processing and is preparing it for commercialization. The company plans to use its recent Series A proceeds to improve cloud and on‑premises products, commercialize VDPU, expand globally, and hire key talent. Dnotitia is also moving forward with IPO preparations, naming Korea Investment & Securities and Shinhan Securities as joint lead managers.

Participated · Series B · Mar 2026

ActionPower leverages internally-built multimodal AI models capable of processing voice, text, and images to boost productivity across B2C and B2B markets. Its flagship consumer product, Daglo, recorded nearly 4× year-over-year revenue growth and has processed a cumulative 13 million hours of voice data (as of 2025). On the enterprise side, the company’s revenue expanded about 40 % year-over-year, aided by support for both on-prem and cloud deployments. Core customers include DB Life Insurance, Hancom, Daegu City Hall, Seoul National University Hospital, and KT Skylife. ActionPower claims more than 70 domestic and international patents and multiple publications in global AI journals that validate its personalization and high-performance embedding technologies. Management plans to evolve its solutions from simple task automation toward decision-supportive AI agents and to accelerate international expansion using the fresh capital. Cumulative funding for the company now exceeds ₩20 billion (≈US $15 million).

Participated · Seed · Jan 2023

XCENA designs the MX1, a prototype chip that brings compute into the memory module via CXL to process data inside DRAM modules and reduce expensive round trips between CPUs, GPUs, and memory. The company says the approach handles preprocessing, KV cache management, and data caching within memory, potentially shrinking infrastructure needs (claiming workloads that once required 10 servers could run on one). XCENA’s cores are built on RISC-V and the company emphasizes vertical integration, designing its own memory hierarchy, interconnect bus, and DRAM controller. The startup was founded in 2022 by Jin Kim, Dohun Kim, and Harry Juhyun Kim and has offices in Pangyo and Sunnyvale with over 90 staff. XCENA positions itself against rivals like Astera Labs and Marvell and plans mass production at Samsung foundries by the end of 2026 with revenue expected to begin in 2027; to date it has raised $185 million.

Participated · Series A · Aug 2021

S-Alpha Therapeutics develops digital therapeutics that combine information technology and biology, with several products in an R&D pipeline. The company is advancing SAT-001, its lead program for pediatric myopia, which is undergoing clinical evaluation at multiple sites in South Korea and is planned for further trials in the U.S. S-Alpha is also validating SAT-008, aimed at inducing immune-boosting effects, and is exploring business development models around evidence from clinical studies. The company uses its Series A proceeds to complete verification of SAT-008 and to support broader R&D across its pipeline. Founded in 2019 and based in Seoul, S-Alpha has positioned clinical validation as a near-term priority to demonstrate safety and efficacy. Financially, the company completed a $2.7M seed round in 2020 and closed an $8.7M Series A in 2021 to fund its development plans. S-Alpha Therapeutics is a Seoul, South Korea–based digital therapeutics company with platform technologies that enable digital devices to treat multiple disease areas. Its pipeline includes products in ophthalmology, neuropsychiatry, cancer, and immunology, with a lead product, SAT-001, aimed at treating eye disease. SAT-001 is in the process of regulatory submission to start clinical studies in Korea following MFDS guidance from June 2020, and the company completed a meeting with the US FDA in July 2020 to discuss development. S-Alpha is preparing to launch clinical studies in the United States and intends to use recent funding to execute those trials. The company is led by CEO Seung Eun Choi and Chief Medical Officer Dr. Myung Joon Kim. Financially, S-Alpha completed a seed round to support its clinical development activities.